6-Mercaptopurine
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
| ID | DRUG-MERCAPTOPURINE |
|---|---|
| Tipo | Fármaco |
| Aliaces | 6-МеркаптопуринLangostas, de lana o de abetonaPurinetholEl purixán |
| Situación | reviewed 2026-04-27 | pending_clinical_signoff |
| Enfermedades | DIS-B-ALL |
| Fuentes | SRC-NCCN-BCELL-2025 |
Datos sobre drogas
| Clase | Antineoplásico — análogo de purina (tiopurina) |
|---|---|
| Mecanismo | Purine antagonist; converted by HGPRT to thio-IMP, which inhibits de novo purine biosynthesis and incorporates into DNA/RNA as thio-dGTP, causing chain termination and triggering apoptosis. Backbone of B-ALL maintenance (POMP / vincristine + MTX + 6-MP + prednisone) for 2-3 years post-induction-consolidation. |
| Dosificación típica | B-ALL maintenance: 50-75 mg/m² PO daily (continuous), titrated to ANC 0.75-1.5 × 10⁹/L and platelets >75 × 10⁹/L. Dose adjusted by TPMT/NUDT15 genotype if measured (intermediate metabolizers ~50% reduction; poor metabolizers ~10% of standard dose or avoid). |
| Ucrania registrada | Cierto |
| NSZU reembolsado | Cierto |
| Ucrania verificada por última vez | 2026-04-27 |
Advertencias
- Severe myelosuppression (especially in TPMT- or NUDT15-deficient patients) — genotype testing recommended before initiation
- Hepatotoxicidad, incluyendo enfermedad veno-oclusiva hepática
Notas
Cornerstone of B-ALL maintenance (POMP regimen, 2-3 years post-induction- consolidation). TPMT and NUDT15 genotyping should be performed pre-initiation when available — poor metabolizers require dramatic dose reduction or alternative therapy. Take on empty stomach (food + dairy reduce absorption ~25%). Avoid allopurinol coadministration without dose reduction. Bedtime dosing improves tolerance.
Utilizado por
Esquema terapéutico
REG-POMP-B-ALL-MAINTENANCE- POMP maintenance — B-ALL post-induction-consolidation (vincristine + 6-MP + MTX + prednis...